Analysis Bayer’s Clinical Pipeline and Factory Innovation Face Off Against a Mountain of Debt
Bayer is entering its annual general meeting with a tale of two narratives. On one side, the pharmaceuticals division is delivering tangible progress in both neurology and nephrology, while a...